Informations générales (source: ClinicalTrials.gov)
Characterization of the Mechanisms of Action of Resistance to Azacitidine in High-risk Myelodysplastic Syndromes and Acute Myeloid Leukemia With Multilineage Dysplasia
Observational
Centre Hospitalier Universitaire de Nice (Voir sur ClinicalTrials)
septembre 2010
septembre 2025
17 mai 2025
Myelodysplastic syndromes (MDS) are frequent diseases in elderly patients (median age: 71
years). IPSS classification defines low risk (Low and Intermediate 1), and high risk
(Intermediate 2 and High) MDS. High-risk MDS (MDS-HR) have a high risk of transformation
into acute leukemia with multilineage dysplasia (AML-DML). The success of Azacitidine has
been mainly achieved through a rigorous empirical and clinical research, but the
molecular mechanisms by which this molecule exerts its effects remain poorly
characterized. The primary mode of action of Azacytidine is through DNA demethylation,
and integration in to mRNA that favor traduction inhibition. The impact of this molecule
on various cell death programs involved in the elimination of leukemic cells : apoptosis
and autophagy is currently poorly known.
The research program and clinical studies we proposed focus on two major aspects:
- Main objective: Molecular mechanism of action and resistance to Azacitidine: Role of
apoptosis versus autophagy.
- Secondary Objective: Reversion of Azacytidine resistance using different drugs
targeting apoptosis and/or autophagy. Our laboratory has identified new molecules to
selectively induce different types of cell death (apoptosis or autophagy).
Etablissements
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| Centre Antoine Lacassagne - Nice - France | Vanina OLIVERI, Project Manager | Contact (sur clinicalTrials) | |||
| CH d'Antibes - Antibes - France | Vanina OLIVERI, Project Manaer | Contact (sur clinicalTrials) | |||
| CHU de Nice - Hôpital de l'Archet - 06200 - Nice - France | Vanina OLIVERI, Project Manager | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
- Age ≥ 18 years
- High Risk or Intermediate 2 MDS (IPSS)
- AML-MD (WHO classification)
- Treatment with minimum three to six cycles of Azacitidine
- Informed consent form signed
- Age ≥ 18 years
- High Risk or Intermediate 2 MDS (IPSS)
- AML-MD (WHO classification)
- Treatment with minimum three to six cycles of Azacitidine
- Informed consent form signed
- Treatment with others chemotherapies alone or in association